Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,647 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,647 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03904108 | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have… | Phase 2 | terminated | Apr 4, 2019 | ROGER S KERESZTES MD | insufficient patient population to complete trial as planned | Other (stated, no rule matched) |
| NCT02385812 | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma | Phase 2 | terminated | Mar 11, 2015 | University of Calgary | Low enrollment through COVID pandemic | COVID-19 / pandemic |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Dec 11, 2017 | Sanofi | The study was stopped after interim analysis indicated that overall result was not sufficient to… | Efficacy / futility |
| NCT01487174 | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With… | Phase 3 | terminated | Dec 7, 2011 | Kadmon Corporation, LLC | Kadmon has made a business decision to terminate the study due to slow enrollment. Note the… | Safety / toxicity |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | Phase 4 | terminated | Aug 31, 2018 | Radboud University Medical Center | 81 patients included, difficult inclusion and full inclusion would not change the results | Other (stated, no rule matched) |
| NCT01067144 | Stanford Accelerated Recovery Trial (START) | Phase 3 | terminated | Feb 11, 2010 | Stanford University | Trial met futility stopping point | Efficacy / futility |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2021 | Elpiscience Biopharma, Ltd. | Sponsor's clinical development strategy adjustment | Sponsor / business decision |
| NCT02705404 | A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing | — | terminated | Mar 10, 2016 | Mayo Clinic | Additional mechanisms/trials to enroll these patients exist and competed with the trial. | Enrollment / accrual |
| NCT03054038 | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic… | Phase 1 | terminated | Feb 15, 2017 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer… | Phase 3 | terminated | Feb 3, 2006 | Sumitomo Pharma Co., Ltd. | not stated | Not stated |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT03754244 | A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics | Phase 1 | terminated | Nov 27, 2018 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The enrolment task cannot be gotten within the planned time.It mainly includes patients with… | Enrollment / accrual |
| NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | Phase 1 | terminated | Jun 2, 2015 | NewLink Genetics Corporation | Lack of enrollment and changing landscape of standard of care. | Enrollment / accrual |
| NCT04754815 | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced…(HFHS 21-01) | Phase 2 | withdrawn | Feb 15, 2021 | Shirish Gadgeel | Logistical challenges primarily due to COVID led to delay in starting the study and now is not felt… | COVID-19 / pandemic |
| NCT02932345 | Gefitinib Long-term Survivor Study | — | terminated | Oct 13, 2016 | AstraZeneca | Due to strategic decision, AZ has applied to terminate study at all participating sites and has… | Sponsor / business decision |
| NCT02936947 | Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or… | N/A | terminated | Oct 18, 2016 | Centre Hospitalier Universitaire Vaudois | due to Covid19 restrictions | COVID-19 / pandemic |
| NCT03770299 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small…(CheckMate 9TN) | Phase 2 | withdrawn | Dec 10, 2018 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02662634 | A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell… | Phase 2 | withdrawn | Jan 25, 2016 | GU Research Network, LLC | not stated | Not stated |
| NCT00687986 | Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer(ROSEL) | Phase 3 | terminated | Jun 2, 2008 | Amsterdam UMC, location VUmc | Poor recruitment | Enrollment / accrual |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | Phase 2 | terminated | Jun 1, 2015 | TC Biopharm | not stated | Not stated |
| NCT04061590 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage… | Phase 2 | withdrawn | Aug 20, 2019 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1… | Phase 2 | withdrawn | Jul 14, 2020 | Shirish M Gadgeel | Lack of Accrual | Enrollment / accrual |
| NCT01455389 | TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2011 | Genprex, Inc. | Trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid and… | Other (stated, no rule matched) |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in… | Phase 2 | terminated | Dec 23, 2014 | Novartis Pharmaceuticals | Sponsor decision due to low patient recruitment caused by the change in the treatment landscape of… | Enrollment / accrual |
| NCT04525391 | AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer(SUKSES-N5) | Phase 2 | terminated | Aug 25, 2020 | Se-Hoon Lee | Recommended completion of the study due to SUSAR occurring in other clinical trials conducted with… | Other (stated, no rule matched) |
| NCT04958993 | A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With… | Phase 1 / Phase 2 | terminated | Jul 12, 2021 | Shandong Cancer Hospital and Institute | High incidence of severe radiation pneumonia | Other (stated, no rule matched) |
| NCT03321760 | SABR for T1-2a N1 NSCLC | Phase 2 | withdrawn | Oct 26, 2017 | Indiana University | Decided not to open the study. | Other (stated, no rule matched) |
| NCT04928950 | Charcoal in Lung Cancer Patients Undergoing TEMLA | Phase 2 | withdrawn | Jun 16, 2021 | Masonic Cancer Center, University of Minnesota | Because of logistic challenges and lack of product among other factors, we decided to completely… | Other (stated, no rule matched) |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT04186988 | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer… | Early Phase 1 | withdrawn | Dec 5, 2019 | University of California, Davis | Unable to recruit to study. | Enrollment / accrual |
| NCT03988192 | Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy…(Immuno-VOC) | N/A | terminated | Jun 17, 2019 | Hopital Foch | Evolution of the treatment procedures so that their is no more benefits for patients | Other (stated, no rule matched) |
| NCT03255083 | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor… | Phase 1 | terminated | Aug 21, 2017 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT04758949 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Feb 17, 2021 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT03319316 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non…(SOLUTION) | Phase 2 | withdrawn | Oct 24, 2017 | European Organisation for Research and Treatment of Cancer - EORTC | Interest withdrawn | Other (stated, no rule matched) |
| NCT02963610 | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With… | Phase 1 / Phase 2 | terminated | Nov 15, 2016 | Fox Chase Cancer Center | Study terminated prematurely due to funding/support being withdrawn by grantor | Funding |
| NCT00372073 | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | Phase 2 | terminated | Sep 6, 2006 | Cyclacel Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00885963 | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung… | Phase 2 | terminated | Apr 22, 2009 | Cyclacel Pharmaceuticals, Inc. | Limitation in financial resources. | Funding |
| NCT03443908 | Early Diagnosis and Treatment of Sleep Disordered Breathing in Lung Cancer | — | withdrawn | Feb 23, 2018 | Mark M. Fuster, MD | Study stopped due to lack of enrollment. | Enrollment / accrual |
| NCT03990077 | Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | Phase 1 | terminated | Jun 18, 2019 | Shanghai Kechow Pharma, Inc. | drug development strategy adjustment | Sponsor / business decision |
| NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or… | Phase 2 | terminated | Aug 17, 2009 | SCRI Development Innovations, LLC | Study was terminated due to slow accrual | Enrollment / accrual |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | Phase 1 / Phase 2 | terminated | Nov 15, 2019 | Eli Lilly and Company | The study was terminated due to an unexpected toxicity finding. | Safety / toxicity |
| NCT04282694 | PRogetto Salute Parma(PSP) | — | terminated | Feb 25, 2020 | University of Parma | The worldwide surge of SARS-CoV-2 started during the first week of the study. The Investigators… | Funding |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung… | Phase 2 | terminated | Oct 17, 2016 | NYU Langone Health | This study was terminated as the standard of care for small cell lung cancer changed in 2018 to… | Other (stated, no rule matched) |
| NCT03497026 | Auris Robotic Endoscopy System for Bronchoscopy | N/A | terminated | Apr 13, 2018 | Auris Health, Inc. | Mutual Termination | Other (stated, no rule matched) |
| NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells… | — | terminated | Jan 23, 2018 | National Cancer Institute (NCI) | Investigator left NIH | Investigator |
| NCT00402883 | Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III… | Phase 2 | terminated | Nov 22, 2006 | SCRI Development Innovations, LLC | Terminated due to bevacizumab and chemoradiotherapy toxicity | Safety / toxicity |
| NCT03231475 | Phase I Study of SPH1188-11 in NSCLC(SPH1188-11) | Phase 1 | withdrawn | Jul 27, 2017 | Shanghai Pharmaceuticals Holding Co., Ltd | Board decision | Other (stated, no rule matched) |
| NCT04422210 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax… | Phase 1 | terminated | Jun 9, 2020 | Hoffmann-La Roche | Decision to discontinue the study based on broader development and strategic prioritisation. The… | Sponsor / business decision |
| NCT03998189 | Metabolic and Microbial Profiling of Lung Cancer | N/A | terminated | Jun 26, 2019 | Wake Forest University Health Sciences | Study deemed no longer feasible | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 26, 2022source: clinicaltrials